Last 7 days
-4.4%
Last 30 days
-15.9%
Last 90 days
17.7%
Trailing 12 Months
-68.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -4.42% | -11.67% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | 1.30% | 17.85% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -5.09% | 32.83% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -5.50% | -20.78% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -5.97% | -4.10% | 22.5 | 3.08 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -8.55% | -11.11% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.2B | 2.2M | 109.33% | 133.59% | -10.15 | 1.4K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -10.48% | 10.28% | 30.48 | 2.77 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -5.76% | -54.20% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -20.83% | -73.20% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 772.8M | 285.2M | -9.04% | -42.36% | 3.51 | 2.71 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -12.79% | -47.96% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -36.94% | -53.16% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 379.1M | 51.5M | -14.46% | -5.94% | -5.34 | 7.36 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.0% | 8,124,000,000 | 8,127,000,000 | 8,192,000,000 | 8,325,000,000 | 8,434,000,000 |
S&GA Expenses | -0.5% | 2,625,000,000 | 2,639,000,000 | 2,631,000,000 | 2,640,000,000 | 2,624,000,000 |
EBITDA | -13.3% | 2,729,000,000 | 3,146,000,000 | 2,936,000,000 | 2,406,000,000 | - |
EBITDA Margin | -13.2% | 0.34 | 0.39 | 0.36 | 0.29 | - |
Earnings Before Taxes | -151.8% | -129,000,000 | 249,000,000 | 26,000,000 | -515,000,000 | -1,024,000,000 |
EBT Margin | -151.8% | -0.02 | 0.03 | 0.00 | -0.06 | - |
Interest Expenses | -2.4% | 1,464,000,000 | 1,500,000,000 | 1,466,000,000 | 1,420,000,000 | 1,426,000,000 |
Net Income | -188.6% | -225,000,000 | 254,000,000 | 43,000,000 | -407,000,000 | -948,000,000 |
Net Income Margin | -188.6% | -0.03 | 0.03 | 0.01 | -0.05 | - |
Free Cahsflow | 32.9% | -946,000,000 | -1,409,000,000 | 409,000,000 | 671,000,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -2.3% | 25,686 | 26,298 | 28,171 | 29,090 | 29,202 |
Current Assets | 5.9% | 4,247 | 4,010 | 5,417 | 5,836 | 5,607 |
Cash Equivalents | 16.0% | 564 | 486 | 659 | 1,249 | 582 |
Inventory | 3.2% | 1,090 | 1,056 | 1,073 | 1,045 | 993 |
Net PPE | 6.2% | 1,600 | 1,507 | 1,545 | 1,579 | 1,598 |
Goodwill | -4.1% | 11,547 | 12,044 | 12,266 | 12,427 | 12,457 |
Liabilities | -1.7% | 25,426 | 25,865 | 27,918 | 29,231 | 29,236 |
Current Liabilities | 2.9% | 3,941 | 3,831 | 4,997 | 4,774 | 5,198 |
Long Term Debt | -5.8% | 21,814 | 23,168 | 22,654 | - | - |
LT Debt, Current | 5.1% | 432 | 411 | 150 | - | - |
LT Debt, Non Current | -2.3% | 20,334 | 20,804 | 21,664 | 23,168 | 22,654 |
Shareholder's Equity | 2.8% | 260 | 253 | -34.00 | - | - |
Retained Earnings | -4.7% | -9,186 | -8,776 | -9,175 | -9,030 | -8,961 |
Additional Paid-In Capital | 23.3% | 159 | 129 | 104 | 415 | 462 |
Accumulated Depreciation | - | 1,820 | - | - | - | - |
Shares Outstanding | 0.0% | 362 | 362 | 362 | 361 | 359 |
Minority Interest | -0.6% | 952 | 958 | 946 | 75.00 | 72.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 38.3% | -728 | -1,179 | 648 | 920 | 1,426 |
Share Based Compensation | 1.6% | 126 | 124 | 124 | 129 | 128 |
Cashflow From Investing | -22.7% | -303 | -247 | 394 | 409 | 409 |
Cashflow From Financing | -715.6% | -474 | 77.00 | -1,044 | -802 | -1,513 |
97.3%
72.7%
36.9%
Y-axis is the maximum loss one would have experienced if Bausch Health Companies was unfortunately bought at previous high price.
-20.5%
-18.5%
-13.5%
-17.5%
FIve years rolling returns for Bausch Health Companies.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -4,000 | 41,000 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | new | - | 2,905,620 | 2,905,620 | -% |
2023-02-24 | NATIXIS | added | 97.72 | 44,216,900 | 99,336,900 | 0.56% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -18.79 | -44,912 | 128,088 | -% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -8.35 | -14,071 | 68,929 | -% |
2023-02-17 | Coppell Advisory Solutions Corp. | new | - | 1,256 | 1,256 | -% |
2023-02-16 | MAVERICK CAPITAL LTD | sold off | -100 | -278,000 | - | -% |
2023-02-15 | NOMURA HOLDINGS INC | reduced | -28.3 | -40,001,000 | 74,118,000 | 0.30% |
2023-02-15 | GABELLI & Co INVESTMENT ADVISERS, INC. | added | 20.67 | 10,668 | 113,668 | 0.02% |
2023-02-15 | BERKSHIRE ASSET MANAGEMENT LLC/PA | reduced | -9.24 | -14,176 | 67,824 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | nomura holdings inc | 3.6% | 13,030,352 | SC 13G/A | |
Feb 13, 2023 | goldentree asset management lp | 5.4% | 19,421,054 | SC 13G | |
May 13, 2022 | va partners i, llc | 4.0% | 14,430,901 | SC 13D/A | |
Feb 14, 2022 | nomura holdings inc | 5.4% | 19,515,079 | SC 13G | |
Dec 13, 2021 | glenview capital management, llc | 4.75% | 17,078,657 | SC 13D/A | |
Jun 21, 2021 | va partners i, llc | 5.0% | 17,941,603 | SC 13D/A | |
Apr 23, 2021 | meruelo alex | 5.51% | 19,604,777 | SC 13G | |
Mar 16, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
Mar 11, 2021 | icahn carl c | 3.98% | 14,169,189 | SC 13D/A | |
Feb 24, 2021 | icahn carl c | - | 0 | SC 13D/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 07, 2023 | 4/A | Insider Trading | |
Mar 06, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 8-K | Current Report | |
Feb 23, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-06 | Carson Seana | sold (taxes) | -4,539 | 9.17 | -495 | evp, general counsel |
2023-03-06 | Carson Seana | sold | -4,539 | 9.17 | -495 | evp, general counsel |
2023-03-03 | APPIO THOMAS | sold (taxes) | -93,203 | 9.16 | -10,175 | chief executive officer |
2023-03-03 | Carson Seana | sold | -7,285 | 9.34 | -780 | evp, general counsel |
2023-03-03 | Carson Seana | sold (taxes) | -42,093 | 9.19065 | -4,580 | evp, general counsel |
2023-03-02 | Vadaketh Tom George | sold (taxes) | -37,009 | 9.25 | -4,001 | evp, chief financial officer |
2023-03-02 | Vadaketh Tom George | acquired | - | - | 142,678 | evp, chief financial officer |
2023-03-02 | Carson Seana | acquired | - | - | 95,119 | evp, general counsel |
2023-03-02 | APPIO THOMAS | acquired | - | - | 523,155 | chief executive officer |
2023-03-02 | Carson Seana | sold (taxes) | -55,444 | 9.25 | -5,994 | evp, general counsel |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | |||
Revenues | $ 8,124 | $ 8,434 | $ 8,027 |
Expenses | |||
Selling, general and administrative | 2,625 | 2,624 | 2,367 |
Research and development | 529 | 465 | 452 |
Amortization of intangible assets | 1,215 | 1,375 | 1,645 |
Goodwill impairments | 824 | 469 | 0 |
Asset impairments, including loss on assets held for sale | 15 | 234 | 114 |
Restructuring, integration, separation and IPO costs | 63 | 50 | 22 |
Other expense, net | 35 | 373 | 502 |
Total Expenses | 7,670 | 7,984 | 7,351 |
Operating income | 454 | 450 | 676 |
Interest income | 14 | 7 | 13 |
Interest expense | (1,464) | (1,426) | (1,534) |
Gain (loss) on extinguishment of debt | 875 | (62) | (59) |
Foreign exchange and other | (8) | 7 | (30) |
Loss before income taxes | (129) | (1,024) | (934) |
(Provision for) benefit from income taxes | (83) | 87 | 375 |
Net loss | (212) | (937) | (559) |
Net income attributable to noncontrolling interest | (13) | (11) | (1) |
Net loss attributable to Bausch Health Companies Inc. | $ (225) | $ (948) | $ (560) |
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share) | $ (0.62) | $ (2.64) | $ (1.58) |
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) | $ (0.62) | $ (2.64) | $ (1.58) |
Basic weighted-average common shares (in shares) | 362,000 | 358,900 | 355,000 |
Diluted weighted-average common shares (in shares) | 362,000 | 358,900 | 355,000 |
Product sales | |||
Revenues | |||
Revenues | $ 8,046 | $ 8,342 | $ 7,924 |
Expenses | |||
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | 2,336 | 2,361 | 2,202 |
Other revenues | |||
Revenues | |||
Revenues | 78 | 92 | 103 |
Expenses | |||
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues | $ 28 | $ 33 | $ 47 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 564 | $ 582 |
Restricted cash and other settlement deposits | 27 | 1,537 |
Trade receivables, net | 1,790 | 1,775 |
Inventories, net | 1,090 | 993 |
Prepaid expenses and other current assets | 776 | 720 |
Total current assets | 4,247 | 5,607 |
Property, plant and equipment, net | 1,600 | 1,598 |
Intangible assets, net | 5,800 | 6,948 |
Goodwill | 11,547 | 12,457 |
Deferred tax assets, net | 2,166 | 2,252 |
Other non-current assets | 326 | 340 |
Total assets | 25,686 | 29,202 |
Current liabilities: | ||
Accounts payable | 521 | 407 |
Accrued and other current liabilities | 2,988 | 4,791 |
Current portion of long-term debt | 432 | 0 |
Total current liabilities | 3,941 | 5,198 |
Acquisition-related contingent consideration | 208 | 202 |
Non-current portion of long-term debt | 20,334 | 22,654 |
Deferred tax liabilities, net | 202 | 529 |
Other non-current liabilities | 741 | 653 |
Total liabilities | 25,426 | 29,236 |
Commitments and contingencies (Notes 20 and 21) | ||
Equity (Deficit) | ||
Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748 issued and outstanding at December 31, 2022 and 2021, respectively | 10,391 | 10,317 |
Additional paid-in capital | 159 | 462 |
Accumulated deficit | (9,186) | (8,961) |
Accumulated other comprehensive loss | (2,056) | (1,924) |
Total Bausch Health Companies Inc. shareholders’ deficit | (692) | (106) |
Noncontrolling interest | 952 | 72 |
Total equity (deficit) | 260 | (34) |
Total liabilities and equity (deficit) | $ 25,686 | $ 29,202 |